Strategy Inc (MSTR) Is a Trending Stock: Facts to Know Before Betting on It

Strategy Inc (MSTR) has recently trended but significantly underperformed the S&P 500, declining 15.7% over the past month, while its industry also saw a 2.5% loss. Despite reporting a substantial EPS beat of $32.6 last quarter, the company's current fiscal year earnings estimate stands at -$15.73, representing a 134.1% year-over-year decline and a significant negative revision of 627.3% in the last 30 days. This volatile earnings outlook, combined with an 'F' valuation grade indicating a premium to peers, has led Zacks to assign MSTR a Rank #4 (Sell), forecasting potential near-term underperformance.

Analysis

MicroStrategy (MSTR) has demonstrated significant near-term weakness, with its shares declining 15.7% over the past month, starkly underperforming the S&P 500 composite's 1.9% gain. The fundamental outlook appears challenging, underpinned by a dramatic downward revision in earnings estimates. While the company posted a notable EPS of $32.6 in its last reported quarter, this appears to be an anomaly, as it was the sole earnings beat in the last four quarters. More critically, the consensus earnings estimate for the current fiscal year has been revised down by 627.3% over the last 30 days to a loss of $15.73 per share, representing a 134.1% year-over-year decline. This negative earnings trajectory is coupled with sluggish top-line growth, with revenue forecasts pointing to just +0.7% and +3.9% growth for the current and next fiscal years, respectively. The stock's valuation is also a major concern, as it receives an 'F' grade from Zacks for value, indicating it trades at a significant premium to its peers. These factors culminate in a Zacks Rank #4 (Sell), suggesting a high probability of continued market underperformance.

Key Decisions for Investors

• Given the Zacks Rank #4 (Sell), a sharp 627.3% downward revision in the current fiscal year's earnings estimate, and recent 15.7% stock price underperformance, investors should exercise extreme caution and consider reducing exposure to MSTR.
• The stock's 'F' grade for valuation combined with projected revenue growth below 4% for the next fiscal year indicates a significant risk of multiple compression, making its current premium price difficult to justify.
• The massive one-off EPS surprise last quarter should be viewed with skepticism, as the inconsistent earnings history and negative forward estimates suggest investors should await a sustained trend of positive revisions before establishing or adding to positions.